Given that FGF21 and its analogs have been extensively shown to be beneficial for treating obesity, type 2 diabetes, and MASLD in a number of animal models and humans, ethyl lactate, a dietary chemical component, may have therapeutic potential for treating alcoholic liver diseases and other metabolic disorders. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.